Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1783328 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $0.76Day +1.90%Mkt cap $98M1Y −58.2%Off 52W high −70.6%Vol (1Y) 88.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,825 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest1.1% of sh out |
| Days to cover1.2d |
| 13F net flow (QoQ)+1.51% |
| Top-10 13F concentration81.7% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$9.1M |
| Earnings (TTM)-$124.3M |
| ROE−71.3% |
| Net margin−1256.8% |
| Debt / equity0.26× |
| Sales growth 3Y−8.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−24.4% |
| 1Y−58.2% |
| 3Y−66.3% |
| 5Y−92.9% |
| 10Y−97.1% |
| Since incept. (ann.)−29.6% |
Total return through 2026-07-30 · series begins 2016-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)88.0% |
| Ann. volatility (3Y)86.1% |
| Sharpe (1Y)−0.54 |
| Sharpe (3Y)0.01 |
| Max drawdown (1Y)−70.6% |
| Max drawdown (3Y)−92.2% |
| Beta (3Y vs SPY)2.05 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 8.0M | $8M | — | +0.0% |
| BVF INC/IL | 5.6M | $6M | — | +6.5% |
| BAKER BROS. ADVISORS LP | 2.8M | $3M | — | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $2M | — | new |
| BlackRock, Inc. | 1.8M | $2M | — | −0.4% |
| MILLENNIUM MANAGEMENT LLC | 1.5M | $1M | — | +261.8% |
| RENAISSANCE TECHNOLOGIES LLC | 1.4M | $1M | — | +19.6% |
| Deer Management Co. LLC | 1.2M | $1M | — | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding not shown: no SEC cover-page share count falls within 120 days of the 2026-Q1 quarter end, so any percentage would rest on a count that cannot speak for this quarter. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | −$0.22 | — | $982,000 | −54.8% |
| 2025-12-31 | 2026-03-04 | — | — | $2.6M | +286.0% |
| 2025-09-30 | 2025-11-12 | −$0.28 | — | $2.5M | +139.4% |
| 2025-06-30 | 2025-08-12 | −$0.28 | — | $3.1M | +473.9% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
